Leerink Partnrs Issues Optimistic Outlook for VIR Earnings

Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) - Analysts at Leerink Partnrs upped their Q4 2025 earnings per share (EPS) estimates for Vir Biotechnology in a research report issued on Wednesday, August 6th. Leerink Partnrs analyst R. Ruiz now anticipates that the company will post earnings per share of ($0.62) for the quarter, up from their prior estimate of ($0.68). The consensus estimate for Vir Biotechnology's current full-year earnings is ($3.92) per share. Leerink Partnrs also issued estimates for Vir Biotechnology's FY2026 earnings at ($2.43) EPS, FY2027 earnings at ($1.58) EPS and FY2028 earnings at ($0.64) EPS.

Vir Biotechnology (NASDAQ:VIR - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.72) by ($0.08). Vir Biotechnology had a negative net margin of 2,895.94% and a negative return on equity of 50.22%. The business had revenue of $1.21 million during the quarter, compared to analyst estimates of $2.38 million. During the same period in the prior year, the business posted ($1.02) EPS. The company's revenue for the quarter was down 60.5% compared to the same quarter last year.

Other research analysts have also issued reports about the company. Needham & Company LLC reaffirmed a "buy" rating and set a $14.00 target price on shares of Vir Biotechnology in a research report on Thursday, May 22nd. The Goldman Sachs Group reduced their target price on Vir Biotechnology from $28.00 to $21.00 and set a "buy" rating for the company in a research note on Thursday, April 17th. Finally, Raymond James Financial began coverage on Vir Biotechnology in a research note on Friday, July 11th. They issued an "outperform" rating for the company. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $30.25.

Vir Biotechnology Price Performance

Shares of NASDAQ VIR traded up $0.08 during mid-day trading on Monday, hitting $4.36. 884,410 shares of the stock traded hands, compared to its average volume of 1,102,691. Vir Biotechnology has a twelve month low of $4.16 and a twelve month high of $14.45. The company has a market cap of $605.69 million, a PE ratio of -1.09 and a beta of 1.18. The firm has a 50 day simple moving average of $5.27 and a two-hundred day simple moving average of $6.36.

Insider Transactions at Vir Biotechnology

In other Vir Biotechnology news, EVP Mark Eisner sold 6,796 shares of Vir Biotechnology stock in a transaction dated Tuesday, July 15th. The stock was sold at an average price of $5.47, for a total transaction of $37,174.12. Following the completion of the transaction, the executive vice president owned 108,204 shares in the company, valued at approximately $591,875.88. The trade was a 5.91% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Vicki L. Sato sold 22,000 shares of the business's stock in a transaction that occurred on Tuesday, July 1st. The stock was sold at an average price of $5.10, for a total value of $112,200.00. Following the completion of the transaction, the director owned 1,298,391 shares in the company, valued at $6,621,794.10. The trade was a 1.67% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 57,582 shares of company stock valued at $294,930 in the last quarter. Company insiders own 16.00% of the company's stock.

Institutional Investors Weigh In On Vir Biotechnology

A number of hedge funds have recently modified their holdings of VIR. Baker BROS. Advisors LP bought a new stake in Vir Biotechnology during the 4th quarter valued at $7,961,000. Point72 Asset Management L.P. grew its position in shares of Vir Biotechnology by 16,169.5% during the 4th quarter. Point72 Asset Management L.P. now owns 848,454 shares of the company's stock valued at $6,228,000 after purchasing an additional 843,239 shares in the last quarter. Dimensional Fund Advisors LP raised its position in Vir Biotechnology by 58.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,915,465 shares of the company's stock valued at $14,059,000 after purchasing an additional 703,360 shares in the last quarter. Millennium Management LLC lifted its stake in Vir Biotechnology by 55.3% during the fourth quarter. Millennium Management LLC now owns 1,715,083 shares of the company's stock worth $12,589,000 after purchasing an additional 610,367 shares during the last quarter. Finally, Nordea Investment Management AB lifted its stake in Vir Biotechnology by 403.7% during the second quarter. Nordea Investment Management AB now owns 704,377 shares of the company's stock worth $3,677,000 after purchasing an additional 564,537 shares during the last quarter. Institutional investors own 65.32% of the company's stock.

About Vir Biotechnology

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).